Clover Health Investments (CLOV) is back in focus as fresh commentary underscores a key shift. Despite a tough year for medical costs, management now expects GAAP profitability in 2026, a potential turning point for the insurer.

See our latest analysis for Clover Health Investments.

At a latest share price of $2.49, Clover’s 30 day share price return of minus 29.46 percent and year to date share price return of minus 20.45 percent show fading near term momentum. However, a 3 year total shareholder return of 109.24 percent hints that investors still see turnaround potential if management delivers on profitability.

If this shift in sentiment has you rethinking the broader healthcare space, it could be a good time to explore other healthcare stocks that might offer a different balance of growth and risk.

With the stock trading below analyst targets yet still digesting medical cost pressures, investors face a key question: Is Clover Health quietly undervalued ahead of 2026 profitability, or has the market already priced in its next leg of growth?

With Clover Health Investments last closing at $2.49 versus a narrative fair value of $3.23, the most followed view argues the current price leaves meaningful upside.

The analysts have a consensus price target of $3.65 for Clover Health Investments based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $5.0, and the most bearish reporting a price target of just $2.5.

Read the complete narrative.

Want to see the math behind that upside gap? This narrative leans on rapid revenue expansion, a sharp margin swing, and a punchy future earnings multiple. Curious which assumptions really carry the valuation?

Result: Fair Value of $3.23 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, sustained medical cost inflation or adverse Medicare Advantage reimbursement changes could quickly erode margins and challenge the case for Clover’s 2026 profitability inflection.

Find out about the key risks to this Clover Health Investments narrative.

If you see the story differently or want to stress test every assumption with your own numbers, you can build a full view in minutes: Do it your way

A great starting point for your Clover Health Investments research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Before you move on, consider your next steps by scanning focused stock ideas on Simply Wall Street so you are not relying on Clover alone.

Strengthen your portfolio’s income stream by targeting steady payers using 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">these 14 dividend stocks with yields > 3% with the potential to support long term returns.

Explore the AI transformation by reviewing these 25 AI penny stocks for companies involved in this area.

Explore these 935 undervalued stocks based on cash flows for stocks where market prices may differ from underlying cash flow strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CLOV.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com